Accessibility Menu
Cogstate logo

Cogstate(ASX) CGS

Market CapA$467.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+471%
5 Year+63%
1 Year+66%
1 Month-1%
A$2.74
-0.36%
-0.01Today
Cogstate last closing stock price
MetricPriceDate
Last closeAUD 2.742026-08-13
Cogstate stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.18%AUD 2.632026-08-06
1 month-1.44%AUD 2.782026-07-14
3 month+10.04%AUD 2.492026-05-15
Year to date+21.24%AUD 2.262025-12-31
1 year+65.92%AUD 1.652025-08-13
3 year+90.43%AUD 1.442023-08-14
5 year+62.51%AUD 1.692021-08-13
Since inception+471.34%AUD 0.482004-02-16

Cogstate Financials at a Glance

Market Cap

A$467.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$105.91M

Net Income (TTM)

$18.39M

EPS (TTM)

A$0.10

P/E Ratio

28.06

Dividend

A$0.02

Beta (Volatility)

-0.06 (Low)

Price

A$2.74

Volume

849,793

Open

A$2.75

Previous Close

A$2.74

Daily Range

A$2.69 - A$2.80

52-Week Range

A$1.57 - A$3.01

Estimated Earnings Date

Aug 18, 2026

CGS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cogstate

Cogstate Limited is a Melbourne-based neuroscience technology company that specializes in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Established in 1999, the company serves pharmaceutical, biotechnology, and healthcare sectors with innovative cognitive services.

Products and Services
  • Computerized cognitive assessments for clinical trials
  • Cognigram system for early identification of cognitive decline
  • Comprehensive project and data management services
Growth Outlook
  • Participation in approximately 1,800 academic research initiatives
  • Strong demand for cognitive assessment tools in clinical trials
  • Expansion of healthcare segment with innovative solutions
Financial Highlights
  • Recent quarterly revenue of 26.25 million USD, showing growth
  • Trailing twelve months (TTM) net income margin of 19.63%
  • Current ratio of 3.96 indicates strong liquidity position
Cogstate Limited operates through two main divisions: Clinical Trials and Healthcare. The Clinical Trials segment focuses on delivering technology and support services to measure the impact of various interventions on human participants. The Healthcare segment, featuring the Cognigram system, aids primary care physicians in identifying cognitive decline early, enhancing patient care. The company has demonstrated a robust growth trajectory, evidenced by its participation in numerous academic research initiatives and the increasing demand for its cognitive assessment tools. The recent quarterly revenue reflects a positive trend, indicating the effectiveness of its business model and the potential for future expansion. Financially, Cogstate maintains a strong liquidity position, as indicated by its current ratio of 3.96, which suggests the ability to cover short-term obligations comfortably. The net income margin of 19.63% highlights the company's profitability, making it an attractive option for potential investors interested in the healthcare technology sector.
AI Generated • Jul 21, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

410

CEO

Bradley John O'Connor

Website

www.cogstate.com

Headquarters

Melbourne, VIC 3000, AU

CGS Financials

Key Financial Metrics (TTM)

Gross Margin

34.73%

Operating Margin

21.31%

Net Income Margin

19.63%

Return on Equity

22.19%

Return on Capital

14.57%

Return on Assets

16.23%

Earnings Yield

3.56%

Dividend Yield

0.73%

Payout Ratio

20.72%

Stock Overview

Market Cap

A$467.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

169.92M

Volume

849.79K

Avg. Volume

270.93K

Financials (TTM)

Gross Profit

$43.65M

Operating Income

$25.15M

EBITDA

$27.58M

Operating Cash Flow

$21.50M

Capital Expenditure

-$870.55K

Free Cash Flow

$20.63M

Cash & ST Invst.

$34.07M

Total Debt

$716.74K

Cogstate Performance Analysis

Cogstate annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 62,017,426N/A
20232023-06-30USD 60,132,082-3.0%
20242024-06-30USD 66,264,00410.2%
20252025-06-30USD 81,977,01923.7%
Cogstate sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3036.4%
Q22024-12-31-6.8%
Q42025-06-3025.3%
Q22025-12-31-12.5%
Cogstate annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD 0.06N/A
20232023-06-30USD 0.03-48.6%
20242024-06-30USD 0.0559.5%
20252025-06-30USD 0.0987.5%
Cogstate sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3066.7%
Q22024-12-3112.0%
Q42025-06-3065.2%
Q22025-12-31-29.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$26.25M

+39.3%

Gross Profit

$7.26M

+196.4%

Gross Margin

27.66%

N/A

Market Cap

A$467.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.92M

N/A

Employees

160

N/A

Net Income

$4.62M

+120.6%

EBITDA

$5.32M

+188.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$34.07M

+34.9%

Total Debt

$716.74K

+38.1%

Accounts Receivable

$13.72M

+66.9%

Inventory

$0.00

N/A

Long Term Debt

$602.17K

+39283.5%

Short Term Debt

$114.57K

-77.9%

Return on Assets

16.23%

N/A

Return on Invested Capital

21.73%

N/A

Free Cash Flow

$2.54M

+423.4%

Operating Cash Flow

$2.92M

+3921.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCA.AXOceania Healthcare Limited
A$0.66-2.24%
CUV.AXClinuvel Pharmaceuticals Limited
A$9.59+0.95%
ACL.AXAustralian Clinical Labs Limited
A$2.36+1.72%
AFP.AXAFT Pharmaceuticals Limited
A$3.87+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.62+0.07%
ONDSOndas
$8.93-0.09%
SMCISuper Micro Computer
$39.34+0.05%
SPCXSpace Exploration Technologies
$141.98-0.03%

Questions About CGS

What is the current price of Cogstate?

Cogstate is trading at A$2.74 per share.

What is the 52-week range for Cogstate?

Over the past 52 weeks, Cogstate has traded between A$1.57 and A$3.01.

How much debt does Cogstate have?

As of the most recent reporting period, Cogstate reported total debt of $717.06K.

How much cash does Cogstate have on hand?

Cogstate reported $54.27M in cash and cash equivalents in its most recent financial results.

What is Cogstate’s dividend yield?

Cogstate currently has a dividend yield of 0.73%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services